Mercer Global Advisors
NVAX icon

Mercer Global Advisors’s Novavax NVAX Stock Holding History

Mercer Global Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,742
Closed -$86.6K – 2711
2025
Q2 		$86.6K Buy
+13,742
New +$91K ﹤0.01% 2169
2022
Q2 		– Sell
-2,948
Closed -$217K – 1889
2022
Q1 		$217K Buy
2,948
+632
+27% +$56.4K ﹤0.01% 1687
2021
Q4 		$331K Sell
2,316
-424
-15% -$72.9K ﹤0.01% 1410
2021
Q3 		$568K Buy
2,740
+761
+38% +$168K ﹤0.01% 1110
2021
Q2 		$420K Buy
+1,979
New +$363K ﹤0.01% 1228

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mercer Global Advisors's NVAX Position: Q3 2025 in Review

Mercer Global Advisors sold out of Novavax (NVAX) in Q3 2025, closing a stake of 13,742 shares — an estimated $86.6K sold.

Mercer Global Advisors first reported a position in NVAX in Q2 2021 and held it in 5 quarters. The position peaked at $568K in Q3 2021. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

  • Mercer Global Advisors reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
  • Mercer Global Advisors sold 13,742 Novavax shares in Q3 2025, an estimated $86.6K.
  • Mercer Global Advisors first reported a position in Novavax in Q2 2021 and held it in 5 quarters.
  • Mercer Global Advisors's Novavax position peaked at $568K in Q3 2021.
  • 249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on Mercer Global Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.